Anthelmin 230 mg/20 mg film-coated tablets for cats

Authorised

- Praziquantel
- Pyrantel embonate

Product identification

Medicine name:
Anthelmin 230 mg/20 mg film-coated tablets for cats
Dehinel, 230 mg/20 mg õhukese polümeerikattega tabletid kassidele

Active substance:
Praziquantel
Pyrantel embonate

Target species:
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Praziquantel
20.00 milligram(s) / 1.00 Tablet

Pyrantel embonate
230.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Film-coated tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP52AA51

Legal status of supply:
Veterinary medicinal product not subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Estonia

Available in:
Estonia

Package description:
(ID7) 100 Film-coated tablet: unspecified outer container with 10 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 10 Film-coated tablet, closed with Foil (aluminium)
(ID6) 50 Film-coated tablet: unspecified outer container with 5 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 10 Film-coated tablet, closed with Foil (aluminium)
(ID5) 30 Film-coated tablet: unspecified outer container with 3 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 10 Film-coated tablet, closed with Foil (aluminium)
(ID4) 10 Film-coated tablet: unspecified outer container with 1 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) with 10 Film-coated tablet, closed with Foil (aluminium)
(ID2) 4 Film-coated tablet: unspecified outer container with 2 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) each with 2 Film-coated tablet, closed with Foil (aluminium)
(ID1) 2 Film-coated tablet: unspecified outer container with 1 Blister (oriented polyamide foil; aluminium; polyvinyl chloride) with 2 Film-coated tablet, closed with

Foil (aluminium)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
27/02/2017

Manufacturing sites for batch release:
KRKA tovarna zdravil d.d. Novo mesto
TAD Pharma GmbH
Krka-Farma d.o.o.
Krka-Farma d.o.o.

Responsible authority:
State Agency Of Medicines

Authorisation number:
2015

Date of authorisation status change:
27/02/2017

Reference member state:
Germany

Procedure number:
DE/V/0160/001

Concerned member states:
Austria Belgium Bulgaria Croatia Czechia Estonia Finland France Hungary

Ireland Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

2402275-paren-20191028.pdf